AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2111979 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate delivered via face mask and nebuliser (infants and adults)
Number of subjects: 16
Study 2111979 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal filtration of aerosol
Number of subjects: 16
Study 111943 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fat load (100 g triglyceride) alone
Number of subjects: 6
Study 111943 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fat load (100 g triglyceride) plus intravenous glucose infusion (0.7 g/kg/h)
Number of subjects: 6
Study 111943 — intervention group
Group type: COMPARATOR
Intervention: Intravenous glucose infusion (0.7 g/kg/h)
Number of subjects: 6
Study 111943 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet for 3 weeks
Number of subjects: 6
Study 30612771 — intervention group
Group type: EXPERIMENTAL
Intervention: TTO+MPFLR
Number of subjects: 42
Study 30612771 — intervention group
Group type: COMPARATOR
Intervention: MPFLRa
Number of subjects: 42
Study 26746221 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry roasted, lightly salted hazelnuts
Number of subjects: 72
Study 26746221 — intervention group
Group type: COMPARATOR
Intervention: Raw hazelnuts
Number of subjects: 72
Study 26746221 — intervention group
Group type: EXPERIMENTAL
Intervention: Both forms of hazelnuts
Number of subjects: 72
Study 26156921 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea gargling solution (30 cc, gargled every 6 hours for 24 hours)
Number of subjects: 121
Study 26156921 — intervention group
Group type: COMPARATOR
Intervention: Distilled water gargling (30 cc, gargled every 6 hours for 24 hours)
Number of subjects: 121
Study 23354336 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 g·kg(‐1) mannitol (group L)
Number of subjects: 80
Study 23354336 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 g·kg(‐1) mannitol (group H)
Number of subjects: 80
Study 23354336 — intervention group
Group type: COMPARATOR
Intervention: Midline shift
Number of subjects: 80
Study 20850351 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative S(+)‐ketamine (0.5 mg/kg as a preincisional bolus followed by a continuous infusion 400 μg/kg/h)
Number of subjects: 80
Study 20850351 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative S(+)‐ketamine
Number of subjects: 80
Study 20850351 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative parexocib (40 mg before extubation and 12 hours postoperatively)
Number of subjects: 80
Study 20850351 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine alone (subpleural paravertebral infusion)
Number of subjects: 80
Study 19252905 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ibuprofen (512 mg, equivalent to 400 mg ibuprofen acid)
Number of subjects: 322
Study 19252905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen/poloxamer (400 mg ibuprofen acid and 120 mg poloxamer 407)
Number of subjects: 322
Study 19252905 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (1000 mg)
Number of subjects: 322
Study 19252905 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ibuprofen
Number of subjects: 322
Study 19252905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen/poloxamer
Number of subjects: 322
Study 19252905 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ibuprofen and Ibuprofen/poloxamer
Number of subjects: 322
Study 17203352 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg given 30 min to 1 hour before biopsy
Number of subjects: 300
Study 17203352 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg given immediately after biopsy
Number of subjects: 300
Study 17203352 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 300
Study 15879863 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (0.5 mg)
Number of subjects: 38
Study 15879863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 15879863 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 38
Study 11678947 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray
Number of subjects: 53
Study 11678947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 9623433 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 1%
Number of subjects: 185
Study 9623433 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.5%
Number of subjects: 185
Study 9623433 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.0%
Number of subjects: 185
Study 9623433 — intervention group
Group type: COMPARATOR
Intervention: Propofol 6 mg kg‐1 h‐1
Number of subjects: 185
Study 8151903 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy for patients with clinically significant LV systolic dysfunction (LV ejection fraction <40%)
Number of subjects: 0
Study 8151903 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy for patients with LV dysfunction and normal LV ejection fraction (diastolic dysfunction)
Number of subjects: 0
Study 8151903 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with systolic dysfunction
Number of subjects: 0
Study 8151903 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with symptoms of heart failure
Number of subjects: 0
Study 3045470 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Gy, 10 fractions, 2-3 times a week
Number of subjects: 1193
Study 3045470 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 Gy, 7 fractions, once in 5 days
Number of subjects: 1193
Study 3045470 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Gy, 4 fractions, once a week
Number of subjects: 1193
Study 3045470 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Gy fractional dose
Number of subjects: 1193
Study 29688503 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 1852
Study 29688503 — intervention group
Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 1852
Study 27171537 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptive rehabilitation treatment with Surfaces for Perceptive Rehabilitation (Su‐Per)
Number of subjects: 20
Study 27171537 — intervention group
Group type: COMPARATOR
Intervention: Conventional group physical therapy treatment
Number of subjects: 20
Study 26173366 — intervention group
Group type: EXPERIMENTAL
Intervention: Social work-led care coordination intervention (one home visit and one to two phone calls)
Number of subjects: 89
Study 26173366 — intervention group
Group type: COMPARATOR
Intervention: Usual care post-discharge
Number of subjects: 89
Study 24152257 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 week after-school dance-based intervention consisting of 40 × 75 minute sessions delivered by external dance instructors
Number of subjects: 594
Study 24152257 — intervention group
Group type: COMPARATOR
Intervention: Control schools (no dance intervention)
Number of subjects: 594
Study 22188731 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose extrafine BDP/F 100/6 μg (1 actuation)
Number of subjects: 18
Study 22188731 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose extrafine BDP/F 100/6 μg (4 actuations)
Number of subjects: 18
Study 22188731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17687758 — intervention group
Group type: EXPERIMENTAL
Intervention: HL (hypoxic rooms)
Number of subjects: 11
Study 17687758 — intervention group
Group type: COMPARATOR
Intervention: LL (1200 m)
Number of subjects: 11
Study 17687758 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects pooled
Number of subjects: 11
Study 16776486 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching of the plantar fascia
Number of subjects: 41
Study 16776486 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcaneal taping
Number of subjects: 41
Study 16776486 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 41
Study 16776486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham taping
Number of subjects: 41
Study 14651722 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD + FM (budesonide 400 microg + formoterol 12 microg)
Number of subjects: 29
Study 14651722 — intervention group
Group type: EXPERIMENTAL
Intervention: FP + SM (fluticasone propionate 250 microg + salmeterol 50 microg)
Number of subjects: 29
Study 14651722 — intervention group
Group type: COMPARATOR
Intervention: BUD + FM
Number of subjects: 29
Study 10992535 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose inhaled steroids plus low dose theophylline (LDT, 400 mg daily)
Number of subjects: 155
Study 10992535 — intervention group
Group type: COMPARATOR
Intervention: Low dose inhaled steroids (LDS, 200 microgram BDP twice daily)
Number of subjects: 155
Study 10992535 — intervention group
Group type: COMPARATOR
Intervention: High dose inhaled steroids (HDS, 500 microgram BDP)
Number of subjects: 155
Study 8712319 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (n = 25)
Number of subjects: 51
Study 8712319 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (n = 26)
Number of subjects: 51
Study 1999128 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irrigation of the pelvis with saline until effluent was clear.
Number of subjects: 200
Study 1999128 — intervention group
Group type: COMPARATOR
Intervention: Drainage alone with all four presacral sump drains placed to suction.
Number of subjects: 200
Study 1999128 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive intraoperative presacral cultures, presence of anaerobes in the presacral space, and duration of pelvic drainage.
Number of subjects: 200
Study 6318647 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy, radiotherapy, or a combination of both (95% of patients treated according to a randomized trial)
Number of subjects: 555
Study 6318647 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy in primarily inoperable patients
Number of subjects: 555
Study 6318647 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard surgical procedure (bilateral salpingo‐oophorectomy with or without hysterectomy, and infracolic omentectomy)
Number of subjects: 555
Study 31370283 — intervention group
Group type: EXPERIMENTAL
Intervention: ESI + E
Number of subjects: 120
Study 31370283 — intervention group
Group type: COMPARATOR
Intervention: E
Number of subjects: 120
Study 31370283 — intervention group
Group type: COMPARATOR
Intervention: ESI
Number of subjects: 120
Study 31370283 — intervention group
Group type: COMPARATOR
Intervention: C
Number of subjects: 120
Study 29059538 — intervention group
Group type: EXPERIMENTAL
Intervention: Yi Shen Jian Gu granules (YSJG)
Number of subjects: 146
Study 29059538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 27009278 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation 5 g/day for 8 weeks
Number of subjects: 20
Study 27009278 — intervention group
Group type: COMPARATOR
Intervention: Coconut oil (CO) control 5 g/day for 8 weeks
Number of subjects: 20
Study 27009278 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 20
Study 27009278 — intervention group
Group type: COMPARATOR
Intervention: Coconut oil (CO) control
Number of subjects: 20
Study 24293371 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (3 times/week; 3 sets, 6-8 repetitions at 75-80 % of the 1-repetition maximum)
Number of subjects: 236
Study 24293371 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 236
Study 24293371 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in fat mass by 1 kg during resistance exercise training
Number of subjects: 236
Study 24293371 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain in lean body mass by 1 kg during resistance exercise training
Number of subjects: 236
Study 24293371 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of blood cholesterol lowering drugs during resistance exercise training
Number of subjects: 236
Study 22494946 — intervention group
Group type: EXPERIMENTAL
Intervention: French‐Canadian version of the Wheelchair Skills Training Program (WSTP)
Number of subjects: 39
Study 22494946 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 39
Study 20004065 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 642
Study 20004065 — intervention group
Group type: COMPARATOR
Intervention: Nicotine lozenge
Number of subjects: 642
Study 17391510 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies including payment to practices and reducing workload for referring doctors.
Number of subjects: 550
Study 17391510 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment of an experienced trial co-ordinator and dedicated researchers.
Number of subjects: 550
Study 17391510 — intervention group
Group type: EXPERIMENTAL
Intervention: National visibility and repeated local publicity by principal investigators.
Number of subjects: 550
Study 17391510 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration between primary and secondary care.
Number of subjects: 550
Study 16027408 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for 4 days
Number of subjects: 44
Study 16027408 — intervention group
Group type: COMPARATOR
Intervention: Extended-release oxybutynin chloride 10 mg/d
Number of subjects: 44
Study 16027408 — intervention group
Group type: COMPARATOR
Intervention: Extended-release tolterodine tartrate 4 mg/d
Number of subjects: 44
Study 11684077 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of micronised fenofibrate
Number of subjects: 29
Study 11684077 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of atorvastatin
Number of subjects: 29
Study 9848522 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-protein powder at 0, 5, 10, and 20 g/d (0-36 mg isoflavones)
Number of subjects: 60
Study 9848522 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented soy products
Number of subjects: 60
Study 9848522 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfermented soy products
Number of subjects: 60
Study 9848522 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber and carbohydrate intake
Number of subjects: 60
Study 9848522 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy challenge
Number of subjects: 60
Study 8017467 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg once daily at night
Number of subjects: 123
Study 8017467 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 123
Study 8017467 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin and Gemfibrozil (comparison)
Number of subjects: 123
Study 8017467 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin and Gemfibrozil (tolerability)
Number of subjects: 123
Study 2597808 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intervention group (further visits to general practitioner for support and monitoring of GGT levels)
Number of subjects: 83
Study 2597808 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (advised by general practitioner to cut alcohol consumption)
Number of subjects: 83
Study 4397654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine
Number of subjects: 91
Study 4397654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 453297 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu 380A
Number of subjects: 1792
Study 453297 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu 300
Number of subjects: 1792
Study 453297 — intervention group
Group type: COMPARATOR
Intervention: TCu 220C
Number of subjects: 1792
Study 30712748 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation techniques performed once a day for 30 minutes over two months
Number of subjects: 80
Study 30712748 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 80
Study 27754572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier use
Number of subjects: 70
Study 25399847 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual Antiplatelet Therapy Study participants
Number of subjects: 1276
Study 25399847 — intervention group
Group type: COMPARATOR
Intervention: CathPCI Registry patients
Number of subjects: 1276
Study 24552494 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline intervention
Number of subjects: 1282
Study 24552494 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic models
Number of subjects: 1282
Study 21931376 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated α‐fetoprotein (AFP)
Number of subjects: 855
Study 21931376 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated des‐γ‐carboxy prothrombin (DCP)
Number of subjects: 855
Study 21931376 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated AFP‐L3
Number of subjects: 855
Study 21931376 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall biomarker performance
Number of subjects: 855
Study 19948623 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence monitoring with feedback (AMF)
Number of subjects: 250
Study 19948623 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma basic care (ABC)
Number of subjects: 250
Study 19948623 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 250
Study 17525586 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 100
Study 17525586 — intervention group
Group type: COMPARATOR
Intervention: hetastarch
Number of subjects: 100
Study 15149250 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal working memory tasks
Number of subjects: 236
Study 15149250 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuospatial working memory tasks
Number of subjects: 236
Study 15149250 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal short-term memory tasks
Number of subjects: 236
Study 15149250 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuospatial short-term memory tasks
Number of subjects: 236
Study 15149250 — intervention group
Group type: EXPERIMENTAL
Intervention: WM tasks
Number of subjects: 236
Study 15149250 — intervention group
Group type: EXPERIMENTAL
Intervention: STM tasks
Number of subjects: 236
Study 11393342 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril 5-20 mg
Number of subjects: 349
Study 11393342 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5-50 mg
Number of subjects: 349
Study 9581728 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg once daily)
Number of subjects: 91
Study 9581728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 8044491 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular use of earplugs
Number of subjects: 44
Study 8044491 — intervention group
Group type: COMPARATOR
Intervention: Hearing loss greater than expected for age matched controls
Number of subjects: 44
Study 8044491 — intervention group
Group type: EXPERIMENTAL
Intervention: Racing experience
Number of subjects: 44
Study 3176834 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.1 mg/kg i.m. as premedication 45 min before induction with midazolam 0.3 mg/kg i.v. (Group 1)
Number of subjects: 55
Study 3176834 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg/kg i.m. as premedication 45 min before induction with thiopentone 4 mg/kg (Group 2)
Number of subjects: 55
Study 3176834 — intervention group
Group type: COMPARATOR
Intervention: Calculated i.v. administration curve
Number of subjects: 55
Study 4753236 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol 40 mg oral tablet
Number of subjects: 6
Study 4753236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31965548 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotegrast methyl (240, 480, or 960 mg)
Number of subjects: 8
Study 31965548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30723088 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning Together intervention
Number of subjects: 40
Study 28810669 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention package
Number of subjects: 372
Study 25012764 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive CD-based BLS training programme
Number of subjects: 294
Study 25012764 — intervention group
Group type: COMPARATOR
Intervention: Traditional instructor-led BLS training programme
Number of subjects: 294
Study 25012764 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CD and traditional)
Number of subjects: 294
Study 23864130 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 2737
Study 23864130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2737
Study 21304925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment of malaria (IPTc) with sulphadoxine pyrimethamine plus amodiaquine
Number of subjects: 3014
Study 21304925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3014
Study 19812459 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intensive vascular care
Number of subjects: 3700
Study 17090282 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d.
Number of subjects: 842
Study 17090282 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 2 mg b.i.d.
Number of subjects: 842
Study 17090282 — intervention group
Group type: COMPARATOR
Intervention: Placebo-to-tegaserod (switched from placebo to tegaserod 6 mg b.i.d.)
Number of subjects: 842
Study 15612887 — intervention group
Group type: EXPERIMENTAL
Intervention: SCM‐III 10 mL t.i.d
Number of subjects: 68
Study 15612887 — intervention group
Group type: COMPARATOR
Intervention: Heat-inactivated symbiotic
Number of subjects: 68
Study 11035353 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg orally 48 hours before operation
Number of subjects: 90
Study 11035353 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg orally 24 hours before operation
Number of subjects: 90
Study 11035353 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 800 microg vaginally 2 to 4 hours before operation
Number of subjects: 90
Study 8640072 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous thymopentin (TP5) treatment, 1 g three times a week for three patients, 1 g daily for three patients, 2 g daily for two patients
Number of subjects: 8